A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C Infected Males.
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2014
At a glance
- Drugs MK 8325 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Apr 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 07 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.